Latest Articles about QGEN

QIAGEN Downgraded to Strong Sell - Analyst Blog

Zacks Equity Research — Tue, 21 May 2013 22:24:58 Z

Zacks Investment Research downgraded QIAGEN N.V. ( QGEN ) to a Zacks Rank #5 (Strong Sell) on May 16. Why the Downgrade? Earnings momentum for this molecular diagnostics company has

Pre-Market Most Active for May 14, 2013 : NOK, NLSN, VOD, BAC, TSLA, SNE, BHP, MCP, BBRY, TTWO, QGEN, ZNGA

NASDAQ.com News — Tue, 14 May 2013 16:39:56 Z

The NASDAQ 100 Pre-Market Indicator is down -1.55 to 2,980.54. The total Pre-Market volume is currently 3,855,464 shares traded. The following are the most active stocks for the pre-market

Qiagen Acquires IngenuitySystems - Analyst Blog

Zacks Equity Research — Tue, 30 Apr 2013 22:50:58 Z

In an attempt to manage its growing volume of genomic data, Qiagen ( QGEN ) recently acquired Calif.-based privately owned company, Ingenuity Systems, Inc. Through the acquisition, Qiagen

After-Hours Earnings Report for April 29, 2013 : ESRX, SU, GGP, NEM, SBAC, HTZ, PCL, MAS, ACGL, JEC, PRE, QGEN

NASDAQ.com News — Mon, 29 Apr 2013 22:00:04 Z

The following companies are expected to report earnings after hours on 04/29/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Express Scripts Holding Company

QIAGEN Extends Portfolio - Analyst Blog

Zacks Equity Research — Thu, 28 Mar 2013 23:29:08 Z

Global provider of molecular sample and assay technologies, QIAGEN N.V. ( QGEN ) remains committed to technological advancement and new product introductions as exhibited by its recent

Qiagen in Collaboration with Lilly - Analyst Blog

Zacks Equity Research — Sat, 16 Feb 2013 00:20:01 Z

In an attempt to expand its companion diagnostics portfolio, Qiagen N.V. ( QGEN ) entered into a new co-development agreement with global pharmaceutical product manufacturers Eli Lilly

Halftime Report: Fourth-Quarter Earnings Season

Trefis Team — Fri, 08 Feb 2013 20:34:36 Z

Submitted by Wall St. Daily as part of our contributors program Yesterday , I shared why the Fed is ultimately the one mashing the gas pedal to drive stock prices higher. (Scary thought,

Impressive 4Q for Qiagen - Analyst Blog

Zacks Equity Research — Wed, 30 Jan 2013 18:50:01 Z

Qiagen NV ( QGEN ) reported earnings per share (EPS) of 16 cents in the fourth quarter of 2012, significantly up from the break-even EPS in the year-ago period. After adjusting for certain

After-Hours Earnings Report for January 29, 2013 : AMZN, ACE, BRCM, BXP, VRTX, RHI, QGEN, AJG, JLL, FSL, SLGN, AZPN

NASDAQ.com News — Wed, 30 Jan 2013 00:00:04 Z

The following companies are expected to report earnings after hours on 01/29/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Amazon.com, Inc. ( AMZN ) is

Medtronic Ends SFA II Enrollment - Analyst Blog

Zacks Equity Research — Fri, 25 Jan 2013 04:14:16 Z

Medtronic Inc. ( MDT ) has further strengthened its endovascular business. Recently, this leading medical devices company completed the enrollment in its multicenter, randomized controlled

Qiagen Seeks FDA Approval - Analyst Blog

Zacks Equity Research — Sat, 19 Jan 2013 03:00:01 Z

Qiagen NV ( QGEN ), a key provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions, recently made a regulatory submission

FDA Categorizes Cepheid's New Test - Analyst Blog

Zacks Equity Research — Thu, 17 Jan 2013 00:50:01 Z

Cepheid 's ( CPHD ) Xpert CT/NG test has been recently categorized as 'Moderate Complexity' under the Clinical Laboratory Improvement Amendments (CLIA) by the U.S. Food and Drug

Hologic Widens Diagnostic Biz - Analyst Blog

Zacks Equity Research — Tue, 15 Jan 2013 23:00:01 Z

Recently, Hologic Inc. ( HOLX ), a prominent player in the women's healthcare market, gained the U.S. Food and Drug Administration (FDA) clearance for the commercial launch of its Aptima

Qiagen Beats 2012 Placement Target - Analyst Blog

Zacks Equity Research — Tue, 15 Jan 2013 18:50:01 Z

Qiagen ( QGEN ), a major provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions, recently noted that it exceeded its 2012

QIAGEN Inks Three New Deals - Analyst Blog

Zacks Equity Research — Fri, 11 Jan 2013 01:00:01 Z

In a bid to enhance its Personalized Healthcare diagnostic pipeline, QIAGEN ( QGEN ) inked three new deals to include multiple biomarkers in its portfolio. The biomarkers will guide